This study validated that the EVOO secoiridoids represented by OC are a novel lead scaffold class that can be optimized to create clinically useful and active in vivo SMYD2 inhibitors for application to prevent or suppress the mCRPC recurrence and extend the disease-free survival of PC survivors. Here, SMYD2 is linked to pachyonychia congenita.